Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (970)	11/21/1997 11:46:00 AM
From: David Bogdanoff	Read Replies (1) \| Respond to of 2173

DR: Increasing the sample size by only 20% does relatively little to increase the power of a study. However, if I recall correctly, this is the maximum amount they could increase the study size according to FDA guidelines. Since the target group are patients who do not/will not increase insuling intake during the study, it is only logical that they are trying to increase this subgroup. All this just underscores the difficulties in designing completely valid tests on human subjects that do what they will. I do not think that these test changes justify the current low price of the stock. David